Arch Venture Partners Securing Another $3B Biotech Fund--Genesis—the First University & Lab Originated Commercialization Fund

A major venture capital investor in the biotechnology field is now raising a new $3 billion industry-focused fund as disclosed in a Securities and Exchange Commission regulatory filing. Representing Arch’s 13^th fund, it comes less than two years after closing a comparable fund, representing the biggest one in its history. The fund has a unique history, the result of the coming together of a major academic medical center and federally funded lab.

CFO Mark McDonnell managing director signed the documents.